M&A Deal Summary

Advent International Acquires BioDuro-Sundia

On January 28, 2019, private equity firm Advent International acquired life science company BioDuro-Sundia from PPD

Acquisition Highlights
  • This is Advent International’s 13th transaction in the Life Science sector.
  • This is Advent International’s 76th transaction in the United States.
  • This is Advent International’s 7th transaction in California.

M&A Deal Summary
Date 2019-01-28
Target BioDuro-Sundia
Sector Life Science
Buyer(s) Advent International
Sellers(s) PPD
Deal Type Divestiture

Target

BioDuro-Sundia

Irvine, California, United States
BioDuro-Sundia is a global life science contract research and development organization that provides biopharmaceutical clients and partners with comprehensive, fully integrated drug discovery services spanning target identification to IND filing, through to GMP manufacture of drug substance for clinical trials. BioDuro-Sundia was founded in 1996 and is based in Irvine, California.

Search 202,137 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Advent International

Boston, Massachusetts, United States

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 1984
PE ASSETS 76.0B USD
Size Mega
Type Sector Agnostic
DESCRIPTION

Advent is a global private equity firm that targets investments in North America, Europe, Asia, and Latin America. Advent's emerging market efforts are concentrated in Central Europe and Latin America. Advent seeks transactions valued between $50 million and $5 billion and can commit up to $2 billion of equity capital per investment. Broad areas of interest include business & financial services, retail & consumer, technology, media, & telecoms, healthcare & life sciences, and industrial. Prospective transaction types include buyouts, growth capital financings, take privates, and recapitalizations. Advent was formed in 1984 and is based in Boston, Massachusetts.

DEAL STATS #
Overall 268 of 340
Sector (Life Science) 13 of 21
Type (Divestiture) 22 of 37
State (California) 7 of 12
Country (United States) 76 of 100
Year (2019) 3 of 16
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-01-22 Prisma Medios de Pago

Buenos Aires, Argentina

Prisma Medios de Pago is a provider of payment technology solutions, enabling connections between financial institutions, merchants, and consumers by developing high-quality and secure solutions across the whole payments value chain. Prisma Medios de Pago was founded in 1983 and is based in Buenos Aires, Argentina.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-02-04 Charlotte Russe

San Francisco, California, United States

Charlotte Russe is a fashion brand for young women, offering affordable on-trend apparel, shoes, and accessories for all sizes, with a fun and engaging shopping experience wherever and whenever she wants. Charlotte Russe was founded in 1975 and is based in San Francisco, California.

Sell -

Seller(S) 1

SELLER

PPD

Wilmington, North Carolina, United States
Category Company
Founded 1985
Sector Life Science
Employees26,000
Revenue 4.7B USD (2020)
DESCRIPTION

PPD is a global contract research organization providing drug discovery, development, and lifecycle management services. Its clients and partners primarily include pharmaceutical and biotechnology companies, in addition to medical device companies, academic institutions, and government organizations. With offices in 44 countries and more than 11,000 professionals worldwide, PPDI applies innovative technologies, therapeutic expertise, and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. PPD was founded in 1985 and is based in Wilmington, North Carolina.

DEAL STATS #
Overall 2 of 3
Sector (Life Science) 2 of 3
Type (Divestiture) 2 of 3
State (California) 1 of 1
Country (United States) 2 of 3
Year (2019) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-09-06 Evidera

Bethesda, Maryland, United States

Evidera engages in generating and communicating evidence of product value to inform health care system decisions. For over 30 years, the experts at Evidera have provided health economic, outcomes research, market access, data analytics and epidemiology services and products to life sciences organizations.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-06-03 X-Chem

Waltham, Massachusetts, United States

X-Chem is a biotechnology company that is a provider of DNA-Encoded Library (DEL)-based discovery services. DEL technology, allowing customers to screen billions of compounds simultaneously against a single biological target, is an innovative and high growth segment of the market as pharmaceutical companies look for access to cutting edge scientific expertise to support an increasingly challenging drug discovery process. X-Chem has established partnerships with AbbVie, Alexion, Almirall, Bristol-Myers Squibb, AstraZeneca, Bayer, Department of Defense/Harvard, Gilead, Janssen, Maruho, MD Anderson Cancer Center, Ono, Otsuka, Pfizer, Roche, Sanofi, Taiho Pharma, Vertex, and several other leading pharmaceutical companies, biotechnology organizations, and academic centers. X-Chem was founded in 2009 and is based in Waltham, Massachusetts.

Sell -
Mergr

Product

Company

Legal